Michael Kierny PhD

Michael have 6 years of recombinant antibody engineering experience, mostly in Phage display but also experience in Ribosome display. With these technologies he have performed selections utilizing libraries based in the scFv, Fibronectin III (FN3), and Fork-head associated domain (FHA) scaffolds, against putative biomarker peptides and human signaling proteins.
A variety of the reagents he engineered to be dimers or converted to Fabs or scFv-Fcs and then characterized by ITC, SPR, or competition ELISA. Additionally, he implemented these reagents in biological experiments such as IP, Western Blotting, and tissue staining.
He also worked on developing technology, which is under patent review, to combine the advantages of a Ribosome and Phage-display selection into one process to more quickly develop high affinity antibodies. This led to an Innovation grant to improve and commercialize the method.